CSPC Pharmaceutical Group (1093N) Stock Price & Analysis
1093N Stock Chart & Stats
- Day’s Range
- MXN 16.00 - MXN 16.00
- 52-Week Range
- MXN 16.00 - MXN 16.00
- Previous Close
- MXN 16.00
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 216.20B
- Enterprise Value
- MXN 61.00B
- Total Cash (Recent Filing)
- MXN 18.48B
- Total Debt (Recent Filing)
- MXN 652.37M
- Price to Earnings (P/E)
- 10.2
- Beta
- 0.00
- Next Earnings
- Nov 13, 2026 (Est.)
- EPS Estimate
- 0.22
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 3.79%
Bulls Say, Bears Say
Bulls Say
Very Low Leverage
Extremely low leverage gives CSPC substantial financial flexibility across the next several quarters. A conservative capital structure reduces interest and refinancing pressure, preserves capacity to fund research or commercial expansion, and improves resilience if pharmaceutical demand or earnings weaken.
Strong Pharmaceutical Margins
High gross margins and solid operating profitability indicate that CSPC retains meaningful economics from its pharmaceutical portfolio. This provides internal funding for innovation and commercialization while supporting earnings durability, even though current margins are below earlier peak levels.
Rebounded Free Cash Flow
The 2025 recovery in operating and free cash flow strengthens CSPC’s ability to finance operations, research, and investment without relying heavily on external capital. Stronger cash generation also gives management greater flexibility to sustain the business through uneven earnings periods.
Bears Say
Weak Recent Revenue Growth
Recent revenue performance shows limited top-line momentum after declines in 2023 and 2024. Low-single-digit growth in 2025 may constrain operating leverage and reduce the pace at which CSPC can expand earnings, particularly if portfolio adoption does not accelerate.
Margin Compression
The substantial decline in EBIT margin indicates that profitability has become less efficient than in earlier years, despite still-healthy absolute margins. If this compression persists, it could limit earnings growth, reduce reinvestment capacity, and weaken the benefit of future revenue expansion.
Lower Capital Efficiency
Falling return on equity suggests CSPC is generating less profit from its capital base than it did previously. This weaker efficiency can weigh on sustainable earnings compounding and may indicate that balance-sheet strength is not yet translating into the earlier level of shareholder returns.
CSPC Pharmaceutical Group News
1093N FAQ
What was CSPC Pharmaceutical Group’s price range in the past 12 months?
What is CSPC Pharmaceutical Group’s market cap?
When is CSPC Pharmaceutical Group’s upcoming earnings report date?
How were CSPC Pharmaceutical Group’s earnings last quarter?
Is CSPC Pharmaceutical Group overvalued?
Does CSPC Pharmaceutical Group pay dividends?
What is CSPC Pharmaceutical Group’s EPS estimate?
How many shares outstanding does CSPC Pharmaceutical Group have?
What happened to CSPC Pharmaceutical Group’s price movement after its last earnings report?
Which hedge fund is a major shareholder of CSPC Pharmaceutical Group?
What is the TipRanks Smart Score and how is it calculated?
CSPC Pharmaceutical Group Stock Smart Score
Company Description
CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited, primarily an investment holding entity, is dedicated to the development, production, and distribution of pharmaceutical goods. Its operations span the globe, with a significant presence in the People's Republic of China, across Asia, in the Americas, and throughout Europe. The company structures its business activities into three main divisions: Finished Drugs, Bulk Products, and Functional Food and Other ventures. The company's extensive portfolio of finished drugs encompasses treatments for a wide range of conditions. Key offerings include NBP (available as soft capsules and injections) for acute ischemic stroke, and Oulaining (capsules and injections) addressing mild to moderate memory and cognitive impairments. For neurological disorders, Enxi targets adult idiopathic Parkinson's disease. In oncology, Duomeisu treats lymphoma, multiple myeloma, ovarian and breast cancers, alongside other malignant tumors, while Jinyouli aids in preventing chemotherapy-induced leucopenia and infections, and Keaili is prescribed for breast cancer. Further therapeutic areas covered by CSPC include various infections, with products such as Shuluoke, Nuomoling, Weihong, and Xinweihong. Cardiovascular health is addressed by Xuanning for hypertension and Encun to avert atherosclerotic thrombosis events. Qixiao provides relief for upper respiratory tract infections, and diabetes management is supported by Linmeixin and Shuanglexin. Bone health solutions include Gubang and Gubangjia for postmenopausal osteoporosis. Additionally, Gaoshunsong offers relief for a broad spectrum of inflammatory and pain-related conditions, including arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursitis, tenosynovitis, acute gout, dysmenorrhea, toothache, postoperative pain, lower back pain, sprains, strains, and other soft tissue injuries. Other notable products include Debixin for various types of ulcers and Qimaite for acute and chronic pain management. Beyond finished pharmaceuticals, CSPC also supplies active pharmaceutical ingredients (APIs) like antibiotics, vitamin C, and caffeine. The company further diversifies into functional foods, glucose products, and provides healthcare services. Originally established in 1992, the company initially operated under the name China Pharmaceutical Group Limited before adopting its current designation, CSPC Pharmaceutical Group Limited, in March 2013. Its primary corporate office is situated in Shijiazhuang, within the People's Republic of China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Lei Cai
- Employees
- 18,626
- Website
- www.cspc.com.hk
- Address
- No. 226 Huanghe Street, Shijiazhuang, HE, 050035, CN
CSPC Pharmaceutical Group (1093N) Earnings & Revenues
1093N Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 0 | 1 |
| Technical Analysis | 2 | 0 | 0 |
| Moving Averages | 11 | 0 | 1 |
